
Opinion|Videos|September 11, 2024
Understanding Oligometastatic Disease in Prostate Cancer: Insights from PSMA PET Imaging
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Key opinion leaders examine the role of advanced imaging agents, particularly PSMA PET and other radiotracers, in identifying and defining oligometastatic disease in patients with prostate cancer.
Advertisement
Video content above is prompted by the following:
- How do imaging agents, such as PSMA PET or other radiotracers, contribute to the detection and characterization of oligometastasis in prostate cancer patients?
Advertisement
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
A Closer Look at the Evolution and Emerging Insights with Amyloid and Tau PET for Dementia and Alzheimer’s Disease
2
Study Suggests FDG-PET Better than CT for Assessing Treatment Response for Metastatic Breast Cancer
3
Rethinking Our Approach to Acquisitions of Coronary Computed Tomography Angiography (CCTA) Scans
4
Research Highlights from SCCT 2026
5










